Delayed-release dimethyl fumarate (DMF, also known as gastro-resistant DMF) is effective at lowering disease activity long-term in patients with relapsing-remitting multiple sclerosis (RRMS), according to Eva Havrdova, MD, of Charles University of Prague. The findings are set to be presented in a poster session at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2015) in Barcelona, Spain.
When it comes to treating and studying multiple sclerosis, the correlation between magnetic resonance imaging (MRI) lesions and actual disease activity has been widely disputed. A new analysis says that using MRI lesions as a proxy for disease activity is a sufficient approach when determining primary endpoints in clinical trials.
Doctors appear to be overprescribing fluoroquinolones for women with uncomplicated urinary tract infections.
Canadian researchers found a "troubling trend" in an increase in dentists prescribing antibiotics to patients.
The results from an on-going phase 4 trial add to the growing evidence that teriflunomide is effective for relapsing-remitting multiple sclerosis, according to Patricia K. Coyle, MD, of Stony Brook University in New York.
Comparing current treatment models to lessons learned in the early days of the AIDs epidemic, University of Southern California researchers are advocating that more than just the sickest patients with hepatitis C be treated with new drugs that have much higher cure rates than past regimens.
The risk of developing migraine is increased for those who have low back pain, a low level of education, a heavy physical workload, or participate in heavy recreational activities, but is decreased for those who drink alcohol frequently.
Better understanding the relationship between inflammation and biomarkers could help improve treatments for those with multiple sclerosis.
Young suburban heroin users who were admitted recently to a Princeton, NJ drug rehab facility showed an unexpectedly high incidence of hepatitis C infection.